How severe is CVE-2026-21997?

CVE-2026-21997 has a CVSS 3.x base score of 8.5, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is low, integrity high, and availability none.

Is CVE-2026-21997 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (10th percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2026-21997?

CVE-2026-21997 affects Oracle Life Sciences Empirica Signal. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2026-21997?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

Does CVE-2026-21997 have an EU (EUVD) identifier?

Yes. CVE-2026-21997 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2026-24293.

When was CVE-2026-21997 published?

CVE-2026-21997 was published on 2026-04-21 and last updated on 2026-06-17.

CVE-2026-21997

CVE-2026-21997 is a high-severity vulnerability in Oracle Life Sciences Empirica Signal with a CVSS 3.x base score of 8.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-284.

Key facts

Severity: High (CVSS 3.x base score 8.5)
EPSS exploit prediction: 0% (10th percentile)
Actively exploited: Not listed in CISA KEV
EU (EUVD) id: EUVD-2026-24293
Weakness: CWE-284
Affected product: Oracle Life Sciences Empirica Signal
Published: 2026-04-21
Last modified: 2026-06-17

Description

Vulnerability in the Oracle Life Sciences Empirica Signal product of Oracle Life Science Applications (component: Common Core). Supported versions that are affected are 9.2.1-9.2.3. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Life Sciences Empirica Signal. While the vulnerability is in Oracle Life Sciences Empirica Signal, attacks may significantly impact additional products (scope change). Successful attacks of this vulnerability can result in unauthorized creation, deletion or modification access to critical data or all Oracle Life Sciences Empirica Signal accessible data as well as unauthorized read access to a subset of Oracle Life Sciences Empirica Signal accessible data. CVSS 3.1 Base Score 8.5 (Confidentiality and Integrity impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:H/A:N).

Frequently asked questions

What is CVE-2026-21997?: Vulnerability in the Oracle Life Sciences Empirica Signal product of Oracle Life Science Applications (component: Common Core). Supported versions that are affected are 9.2.1-9.2.3. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Life Sciences Empirica Signal. While the vulnerability is in Oracle Life Sciences Empirica Signal, attacks may significantly impact additional products (scope change). Successful attacks of this vulnerability can result in unauthorized creation, deletion or modification access to critical data or all Oracle Life Sciences Empirica Signal accessible data as well as unauthorized read access to a subset of Oracle Life Sciences Empirica Signal accessible data. CVSS 3.1 Base Score 8.5 (Confidentiality and Integrity impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:H/A:N).
How severe is CVE-2026-21997?: CVE-2026-21997 has a CVSS 3.x base score of 8.5, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is low, integrity high, and availability none.
Is CVE-2026-21997 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (10th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2026-21997?: CVE-2026-21997 affects Oracle Life Sciences Empirica Signal. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2026-21997?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
Does CVE-2026-21997 have an EU (EUVD) identifier?: Yes. CVE-2026-21997 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2026-24293.
When was CVE-2026-21997 published?: CVE-2026-21997 was published on 2026-04-21 and last updated on 2026-06-17.

References

https://www.oracle.com/security-alerts/cpuapr2026.html

Affected products (1)

cpe:2.3:a:oracle:life_sciences_empirica_signal:*:*:*:*:*:*:*:*

Other CWE-284 (Improper Access Control) vulnerabilities

CVE-2026-50746 — Critical (CVSS 10.0): A malicious actor with access to the network could exploit an Improper Access Control vulnerability found in UniFi…
CVE-2026-46978 — Critical (CVSS 10.0): Vulnerability in the Oracle Solaris product of Oracle Systems (component: Remote Administration Daemon). The…
CVE-2026-35308 — Critical (CVSS 10.0): Vulnerability in the Oracle Coherence product of Oracle Fusion Middleware (component: Centralized Third Party Jars).…
CVE-2026-35307 — Critical (CVSS 10.0): Vulnerability in the Oracle Coherence product of Oracle Fusion Middleware (component: Core). Supported versions that…
CVE-2026-46695 — Critical (CVSS 10.0): Boxlite is a sandbox service that allows users to create lightweight virtual machines (Boxes) and launch OCI containers…
CVE-2026-46840 — Critical (CVSS 10.0): Vulnerability in Oracle REST Data Services (component: Backend-as-a-Service). Supported versions that are affected are…

Browse all CWE-284 (Improper Access Control) vulnerabilities →